Drug intelligence / Profile preview

CX03

Development stage: Preclinical
Lead developer: Hangzhou Bangshun Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CX03 is a preclinical-stage small molecule inhibitor targeting the PIM1 kinase, developed by Hangzhou Bangshun Pharmaceutical (also known as Biosun Pharma). PIM1 is a serine/threonine kinase that plays a critical role in cell cycle progression, survival, and apoptosis resistance, and its overexpression is linked to various hematologic malignancies. CX03 is specifically being developed for the treatment of myelofibrosis (MF), primarily as part of a combination therapy regimen. The developer holds global commercial rights and anticipates submitting an Investigational New Drug (IND) application for the candidate in 2027.

Targets

PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)

Beyond the preview

Go deeper on CX03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CX03.

Explore the full profile